Compare LGCB & CURX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGCB | CURX |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 14.5M |
| IPO Year | 2023 | 2025 |
| Metric | LGCB | CURX |
|---|---|---|
| Price | $1.41 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 42.2K | ★ 228.2K |
| Earning Date | 01-30-2026 | 09-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $0.26 |
| 52 Week High | $3.10 | $9.18 |
| Indicator | LGCB | CURX |
|---|---|---|
| Relative Strength Index (RSI) | 34.15 | 52.42 |
| Support Level | N/A | $0.38 |
| Resistance Level | $1.60 | $0.52 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 33.33 | 33.96 |
Linkage Global Inc is a cross-border e-commerce integrated service provider. It provides international e-commerce merchants, overseas brands, import and export trading enterprises, etc. with a globally selected supply chain, digital marketing, e-commerce training, international store, ERP and e-commerce software, social e-commerce and other e-commerce integrated services. The company has two operating segments: Extend from Japan, and Other Subsidiaries from Hong Kong. The company is Committed to building a one-stop cross-border integrated service platform to make cross-border trade easier. Company operates in Japan, Hong Kong and China, with maximum revenue from Japan.
Curanex Pharmaceuticals Inc is engaged in discovering, developing, and commercializing botanical drugs for treating unmet medical needs in patients with inflammatory disease. Its compound, Phyto-N, is in preclinical research for six indications: ulcerative colitis, atopic dermatitis, COVID-19, type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and gout.